Insulet Corporation (PODD)
| Market Cap | 10.06B -54.8% |
| Revenue (ttm) | 2.90B +31.9% |
| Net Income | 302.80M -24.7% |
| EPS | 4.29 -22.7% |
| Shares Out | 69.26M |
| PE Ratio | 34.04 |
| Forward PE | 21.85 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 175,788 |
| Open | 145.33 |
| Previous Close | 146.01 |
| Day's Range | 144.88 - 146.79 |
| 52-Week Range | 141.02 - 354.88 |
| Beta | 1.20 |
| Analysts | Buy |
| Price Target | 244.42 (+68.25%) |
| Earnings Date | May 6, 2026 |
About PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controll... [Read more]
Financial Performance
In 2025, Insulet's revenue was $2.71 billion, an increase of 30.73% compared to the previous year's $2.07 billion. Earnings were $247.10 million, a decrease of -40.93%.
Financial StatementsAnalyst Summary
According to 25 analysts, the average rating for PODD stock is "Buy." The 12-month stock price target is $244.42, which is an increase of 68.25% from the latest price.
News
Insulet price target lowered to $165 from $175 at Citi
Citi lowered the firm’s price target on Insulet (PODD) to $165 from $175 and keeps a Neutral rating on the shares. The firm updated models in the medical technology space…
Insulet to Participate in William Blair 46th Annual Growth Stock Conference
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will prese...
Insulet price target lowered to $205 from $237 at Goldman Sachs
Goldman Sachs analyst David Roman lowered the firm’s price target on Insulet (PODD) to $205 from $237 and keeps a Buy rating on the shares. MedTech has experienced one of…
Insulet price target lowered to $235 from $260 at BTIG
BTIG lowered the firm’s price target on Insulet (PODD) to $235 from $260 and keeps a Buy rating on the shares after the company announced a voluntary medical device correction…
Insulet flags dosing defect in some Omnipod devices, sees up to $50 million cost
Insulet said on Tuesday it is carrying out a voluntary correction of certain insulin pump pods across its Omnipod product lines after identifying a manufacturing issue that could result in patients ...
Insulet initiates voluntary medical device correction for certain Omnipod lots
Insulet (PODD) Corporation announced a voluntary Medical Device Correction for specific lots of Omnipod 5, Omnipod DASH, and Omnipod Insulin Management System Pods due to a manufacturing issue, identi...
Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® Pods in the U.S. and Affected International Markets
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation, Inc. (NASDAQ: PODD) (“Insulet” or the “Company”) today announced a voluntary Medical Device Correction for specific lots of Omnipod® 5, Omnipod DASH...
Insulet assumed with an Outperform at William Blair
William Blair assumed coverage of Insulet (PODD) with an Outperform rating. The firm believes the shares are pricing in a lot of investor concerns relating to it its type 2…
Insulet Transcript: AGM 2026
The meeting highlighted a decade of strong revenue growth, global expansion, and innovation in diabetes care. All board nominees were elected, executive compensation was approved, and auditors ratified. Leadership addressed shareholder concerns about stock performance and future competition.
Insulet price target lowered to $208 from $288 at BofA
BofA lowered the firm’s price target on Insulet (PODD) to $208 from $288 and keeps a Buy rating on the shares. After having hosted 34 medtech companies last week in…
Insulet Transcript: Bank of America Global Healthcare Conference 2026
Q1 saw strong U.S. and international growth, with seasonality impacting new patient starts due to insurance changes. Innovation remains central, with Omnipod 6 and a fully closed loop system for Type 2 diabetes set to drive future growth. Margin expansion and sales force investments support ongoing category penetration.
Insulet Earnings Call Transcript: Q1 2026
Q1 2026 delivered 30% constant currency revenue growth, margin expansion, and strong new customer starts, prompting a raised full-year revenue outlook to 21%-23%. Robust U.S. and international performance, innovation launches, and disciplined execution support confidence in sustained growth and profitability.
Insulet Earnings release: Q1 2026
Insulet released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Insulet Slides: Q1 2026
Insulet has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Insulet Quarterly report: Q1 2026
Insulet has published its Q1 2026 quarterly earnings report on May 6, 2026.
Insulet lifts annual revenue forecast after quarterly beat on strong insulin pump demand
Insulet raised its annual revenue growth forecast on Wednesday after reporting better-than-expected quarterly results, driven by strong demand for its tubeless insulin pumps that eliminate the need ...
Insulet Reports First Quarter 2026 Results
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
Insulet Slides: Investor presentation
Insulet has posted slides in relation to its latest quarterly earnings report, which was published on May 6, 2026.
Insulet Unveils 2025 Sustainability Report Highlighting Strong Momentum Across Key Priorities
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced t...
Insulet Slides: Omnipod® 5 competitive clinical performance presentation
Insulet has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes
ACTON, Mass.--(BUSINESS WIRE)--Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes.
Insulet to Participate in BofA Securities 2026 Health Care Conference
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will prese...
Insulet Proxy statement: Proxy filing
Insulet filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Insulet Proxy statement: Proxy filing
Insulet filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.